A New Lord’s Prayer

given by Lord Metatron, Summer 2005

Our Mother and our Father who are in Heaven, we most highly honor Your Names.  We call forth Your Divinity to be manifest now on Earth as it is in Heaven.  Give us this day our nourishment, spiritually, mentally, emotionally and physically.  Support us in our path and in our growth and lead us away from judgment and fear.  Help us to remember that we are One in our thoughts, words and deeds and that whatever we do to others, we also do to ourselves.  Lead us always toward the Higher Light, for we, as One, are the Kingdom, the Power and the Glory for ever and ever.  So shall it be.  Amen.

http://loveandempowerment.com/prayer.html

Copyright by Reniyah Wolf, Eva Aarrestad and the Love and Empowerment Foundation, 2002-2006, in the Name of Lord Metatron.

Psychiatrists Top List in Drug Maker Gifts


By GARDINER HARRIS
Published: June 27, 2007

WASHINGTON, June 26 — As states begin to require that drug companies disclose their payments to doctors for lectures and other services, a pattern has emerged: psychiatrists earn more money from drug makers than doctors in any other specialty.

How this money may be influencing psychiatrists and other doctors has become one of the most contentious issues in health care. For instance, the more psychiatrists have earned from drug makers, the more they have prescribed a new class of powerful medicines known as atypical antipsychotics to children, for whom the drugs are especially risky and mostly unapproved.

Vermont officials disclosed Tuesday that drug company payments to psychiatrists in the state more than doubled last year, to an average of $45,692 each from $20,835 in 2005. Antipsychotic medicines are among the largest expenses for the state’s Medicaid program.

Over all last year, drug makers spent $2.25 million on marketing payments, fees and travel expenses to Vermont doctors, hospitals and universities, a 2.3 percent increase over the prior year, the state said.

The number most likely represents a small fraction of drug makers’ total marketing expenditures to doctors since it does not include the costs of free drug samples or the salaries of sales representatives and their staff members. According to their income statements, drug makers generally spend twice as much to market drugs as they do to research them.